• The current antifungal pipeline contains several categories

  2023-10-26

  

  The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of

• Natural compounds present in medicinal and or nutritional pl

  2023-10-26

  

  Natural compounds, present in medicinal and/or nutritional plants as well as in macrofungi sources, have stimulated a great interest from the pharmaceutical industry. Different natural compounds such as phenolic compounds, alkaloids, terpenoids among others, have shown strong antiangiogenic effects

• According to average serum fat content of g

  2023-10-26

  

  According to average serum fat content of 6.9 g/L (Phillips et al., 1989) and serum dioxin level from individuals exposed to dioxins as the result of accidents in Seveso (Needham et al., 1997), Taiwan (Guo et al., 2004) and Vietnam (The Tai et al., 2011) the median serum concentration of TCDD would

• br Conclusion br Conflict of interest br

  2023-10-26

  

  Conclusion Conflict of interest Acknowledgments We thank Nancy Kerkvliet for helpful advice. The research in the lab of CE and THS is supported by the Deutsche Forschungsgemeinschaft (grants ES103/7-1 and 9-1, HA7346/2-1). We apologize to all authors whose work could not be cited due to lim

• We have expressed the ECDs of

  2023-10-26

  

  We have expressed the ECDs of the human α1, β1, γ and ɛ AChR subunits in the past using the methylotropic yeast Pichia pastoris as soluble glycosylated proteins [15], [16]. Further work with the γ subunit ECD revealed a marked improvement of the solubility and yield following the mutation of hydroph

• br Acknowledgments We thank the

  2023-10-26

  

  Acknowledgments We thank the anonymous reviewers for their constructive comments on the manuscript, and also thank Dr. Hans-U. Dahms for his comments on the manuscript. This work was supported by a grant from the National Research Foundation (2009-0071218) funded to Young-Mi Lee. This work was al

• Inhibitors of mPGES are considered as

  2023-10-26

  

  Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e

• The following are the supplementary data related to this

  2023-10-26

  

  The following are the supplementary data related to this article. Conflict of interest Acknowledgements Disclosure of interest Introduction Since the introduction of platinum-based chemotherapy, metastatic testicular cancer has become a curable disease and most testicular cancer patient

• AP activation is known to

  2023-10-25

  

  AP-1 activation is known to upregulate downstream target genes including Guvacoline hydrobromide D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered

• It has been demonstrated that the hallmarks

  2023-10-25

  

  It has been demonstrated that the hallmarks of pulmonary fibrosis are a loss of endothelial function and subsequent activation of the immune system, which is considered as a direct outcome affected by intracellular pro-inflammatory responses [26]. Thus, inhibition of early inflammation could be an

• br HIF Blockade in AA Therapy In lieu

  2023-10-25

  

  HIF-α Blockade in AA Therapy In lieu of the evidence supporting a central role for HIF-α signaling in tumor angiogenesis and CC pathobiology, significant efforts have focused on the discovery of small-molecule HIF-α inhibitors (for exhaustive compendia, see [28,44,45]). In brief, inhibitors vary

• In the present study AP B preferentially released

  2023-10-25

  

  In the present study, AP31-B preferentially released hydrophobic UCB 35625 such as leucine and alanine from N-terminal of peptide (Fig. 4). The debittering ability of AP31-B seemed to depend on such substrate specificity, but additional tests against other hydrophobic amino acids are needed to conf

• These mutations induce the gene auto

  2023-10-25

  

  These mutations induce the gene auto-activation in 10–40% of adenocarcinomas, triggering the EGFR-signaling pathway in the absence of ligand. That leads to an uncontrolled acceleration of cell proliferation, survival and anti-apoptotic signals (Couraud et al., 2012). The frequency of these mutations

• The lack of specific PARP inhibitors prevents

  2023-10-25

  

  The lack of specific PARP inhibitors prevents our understanding of how TIPARP or perhaps other PARPs affect AHR signaling. Current inhibitors are based on NAM and were designed to inhibit PARP1 [59]. Many of them do not effectively inhibit mono-ADP-ribosyltransferases and their ability to inhibit T

• Introduction A defining feature of

  2023-10-25

  

  Introduction A defining feature of cancer cells is disruption of the normal controls of the cell cycle; a tumor suppressor or inhibitor may act by restricting progression of the cell cycle. P27 (also known as cyclin-dependent kinase inhibitor 1B, P27, or Kip1) is a putative cell-cycle inhibitor pro

14015 records 225/935 page Previous Next First page 上5页 221222223224225 下5页 Last page